Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 12/20 | 0.77 |
| ▸ | JAK1 | P23458 | 12/20 | 0.77 |
| ▸ | TYK2 | P29597 | 3/20 | 0.71 |
| ▸ | JAK3 | P52333 | 2/20 | 0.71 |
| ▸ | IKBKB | O14920 | 1/20 | 0.71 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.71 |
| ▸ | LCK | P06239 | 1/20 | 0.71 |
| ▸ | SYK | P43405 | 1/20 | 0.71 |
| ▸ | GSK3B | P49841 | 1/20 | 0.71 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2237531 | 0.87 | JAK2 (1.00) | JAK2JAK1TYK2JAK3IKBKB | |
| SCHEMBL2185993 | 0.87 | JAK2 (0.82) | JAK2JAK1TYK2JAK3IKBKB | |
| SCHEMBL11916701 | 0.87 | JAK1 (1.00) | JAK2JAK1TYK2JAK3IKBKB | |
| SCHEMBL2239364 | 0.86 | JAK1 (1.00) | JAK2JAK1TYK2JAK3IKBKB | |
| SCHEMBL7960595 | 0.86 | JAK2 (0.80) | JAK2JAK1TYK2JAK3IKBKB | |
| SCHEMBL13031260 | 0.86 | JAK1 (1.00) | JAK2JAK1TYK2JAK3IKBKB | |
| SCHEMBL2238602 | 0.86 | JAK2 (0.80) | JAK2JAK1TYK2JAK3IKBKB | |
| SCHEMBL13031226 | 0.86 | JAK2 (0.82) | JAK2JAK1TYK2JAK3IKBKB | |
| SCHEMBL13031299 | 0.86 | JAK2 (0.80) | JAK2JAK1TYK2JAK3IKBKB | |
| SCHEMBL7963625 | 0.86 | JAK2 (0.80) | JAK2JAK1TYK2JAK3IKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12558360-B2 | Compound useful for the treatment of degenerative and inflammatory diseases | ALFASIGMA S.P.A. (IT) | 2026-02-24 | — | — | US | disclosed |
| US-20240325405-A1 | COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | ALFASIGMA S.P.A. (IT) | 2024-10-03 | — | — | US | disclosed |
| US-12042498-B2 | Compound useful for the treatment of degenerative and inflammatory diseases | ALFASIGMA S.P.A. (IT) | 2024-07-23 | — | — | US | disclosed |
| WO-2023082839-A1 | FILGOTINIB PREPARATION METHOD | 奥锐特药业(天津)有限公司 | 2023-05-19 | — | — | WO | disclosed |
| CN-112851682-B | Substituted pyridine amide compound and application thereof | 深圳市塔吉瑞生物医药有限公司 | 2022-10-25 | — | — | CN | disclosed |
| US-20220185810-A1 | Novel Process for the Preparation of Filgotinib and Intermediates Thereof | UNICHEM LABORATORIES LIMITED (IN) | 2022-06-16 | — | — | US | disclosed |
| US-20210369727-A1 | NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | ALFASIGMA S.P.A. (IT) | 2021-12-02 | — | — | US | disclosed |
| US-11000528-B2 | Compound useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2021-05-11 | — | — | US | disclosed |
| WO-2020201975-A2 | NOVEL PROCESS FOR THE PREPARATION OF FILGOTINIB AND INTERMEDIATES THEREOF | UNICHEM LABORATORIES LIMITED (IN) | 2020-10-08 | — | — | WO | disclosed |
| US-10328081-B2 | Compound useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2019-06-25 | — | — | US | disclosed |
| US-8853240-B2 | Compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2014-10-07 | — | — | US | disclosed |
| US-8563545-B2 | Compound useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2013-10-22 | — | — | US | disclosed |
| US-8563545-B2 | Compound useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2013-10-22 | — | — | US | disclosed |
| US-20120142678-A1 | NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV | 2012-06-07 | — | — | US | disclosed |
| US-20120142678-A1 | NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV | 2012-06-07 | — | — | US | disclosed |
| US-8088764-B2 | Compound useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2012-01-03 | — | — | US | disclosed |
| US-20110190260-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | ALFASIGMA S.P.A. (IT) | 2011-08-04 | — | — | US | disclosed |
| US-20110190260-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | ALFASIGMA S.P.A. (IT) | 2011-08-04 | — | — | US | disclosed |
| US-20100331319-A1 | NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | ALFASIGMA S.P.A. (IT) | 2010-12-30 | — | — | US | disclosed |
| WO-2010010190-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2010-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240325405-A1 | COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | IL6, BMP6, JAK1 | JAK2 5/4885JAK1 3/4885TYK2 79/4885 |
| US-12558360-B2 | Compound useful for the treatment of degenerative and inflammatory diseases | JAK1, IL6, STAT3 | JAK2 8/4885JAK1 1/4885TYK2 62/4885 |
| US-10328081-B2 | Compound useful for the treatment of degenerative and inflammatory diseases | IL6, JAK1, JAK2 | JAK2 3/4885JAK1 2/4885TYK2 65/4885 |
| US-20100331319-A1 | NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | IL6, JAK1, BMP6 | JAK2 9/4885JAK1 2/4885TYK2 52/4885 |
| US-20110190260-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | TRAF6, IL6, TLR6 | JAK2 174/4885JAK1 84/4885TYK2 171/4885 |
| US-20220185810-A1 | Novel Process for the Preparation of Filgotinib and Intermediates Thereof | ABL1, JAK1, JAK3 | JAK2 4/4885JAK1 2/4885TYK2 23/4885 |
| US-20120142678-A1 | NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | IL6, JAK1, BMP6 | JAK2 9/4885JAK1 2/4885TYK2 52/4885 |
| US-12042498-B2 | Compound useful for the treatment of degenerative and inflammatory diseases | IL6, JAK1, BMP6 | JAK2 5/4885JAK1 2/4885TYK2 100/4885 |
| US-20210369727-A1 | NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | IL6, JAK1, BMP6 | JAK2 9/4885JAK1 2/4885TYK2 52/4885 |
| US-11000528-B2 | Compound useful for the treatment of degenerative and inflammatory diseases | IL6, JAK1, BMP6 | JAK2 5/4885JAK1 2/4885TYK2 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.